Helsinki -based CurieflabsA healthTheck company has collected € 6.7 million dollars on the modernway and automatically automatically produce the production of compound drugs, to make patients aimed at the specific, distinct requirement to make it more safe and more suitable.
The funding round was led by private investors with Finland -based growth funding Initiative Springvest, and it includes Business Finland’s € 1 million DITTEC loan. The fund will be used to scale the activities of Curifillabs and to secure high-volume customers in the market.
“The current method of producing synthesized drugs is old and weakly favorable – pharmacy and both of the patients who serve fail. Even with highly trained pharmacists and modern equipment, the process goes unnecessarily labor-intensive, prone to human errors and inconsistent with quality. This may mean that serious conditioning patients cannot take appropriate doses for critical factors such as age, weight and the severity of the disease.
“The consequences are real: a 9-month-old infant in cancer, for example, a carefully customized formula is needed to work together and modernize how we supply personalized drugs-because each patient deserves treatment that each patient needs to be true that fits the truth.” Charlota TopaliasCEO and co-founder of Curiefilab.
Established in 2021, Curifillabs have collected a total of $ 5 million and there are local offices in Finland, the United States and Germany. The team is proud of decades of experience in pharmaceutical and compound industries. CTO and co-founder Niclas Sandler is a professor of pharmaceutical technology at the University of åbo Academy in Finland.
According to Curifillas, custom-rich drugs, which are also known as compound drugs, are not suitable for individual patients due to dose requirements, potential allergies, dose form constraints or drug deficiency. Older population, chronic disease, supply chain barriers, patients’ demand and other factors, global compound markets, currently € 15 billion, are increasing (5.5% CAGR).
DITION TEARS, when a patient needs a personalized medicine synthes,
Curifillabs say that this process is slow, expensive and important for the population of weak patients like children and cancer patients. In fact, 50% of the drugs are not available in dose or formulas for childrenThe Only 1% of the drugs are personalized through compounds despite the increase in demandThe
“Curiphilabs addressed critical inefficiency in pharmaceutical compounds and improves the protection and effectiveness of drugs for weak patients like children. We see the rapid growth of the global compound market that presents an exceptional opportunity for the new solution that the same challenges are likely to be ten times better than existing means to solve” Who is SaudunasariCEO of Springvest PLC.
Curryphilabs has created a solution to automatize the production of compound drugs, which make the process four times faster and enables unlimited dosing flexibility. The compound system solution combines quality control to automat the production process of hardware and software and suitable drugs as well as the carrier agents and active ingredients.
In the process, the incipient bases of Curifillabs, the inactive carrier agents are mixed with the active pharmaceutical elements from raw materials or crushed tablets. The combination is then distributed in the form of a desired dose of tablet or liquid by a desktop-size compound robot. An integrated, cloud-based formulation library guides the pharmacist through a valid compound process and quality control equipment ensures extensive unity and removes the risk of human errors.
“At the same time, entered the US market in Curiefilab, where the huge majority of the mixture produces, the Curiefilabs are located for adequate growth” Golden Continue “We are delighted to be partner with them and we are confident that the agency’s decision -making steps and innovative methods will bring meaningful differences in the daily life of the world worldwideThe “
In addition to the round of the funds, Curryphilabs has announced an AI and robotics-powered, decentralized pharmaceutical manufacturing platform to create a € 5.6 million EU-funded initiative to launch Robofarma. The aim of increasing the crisis throughout Europe by enables producing high-dependency of necessary drugs during care. Curifillabs is ready to lead the initiative, with six partners across Europe.
The EU4 Health Program is meaningful, the project addresses one of the stressful challenges of European healthcare: the fragility and complexity of the chain of pharmaceutical supply during crisis such as epidemics, natural disasters and global disruption. The mission is to develop and establish a skeletrable pharmaceutical production platform for hospital and community pharmacy.
“We have already launched operations in the United States and have aimed to grow rapidly by protecting high-volume customers. Automatic production of personalized Medicine Conscious will provide better drug protection for patients and help pharmacy at low operating expenses. We are going to see a major instance change in the production of personalized medicine sunshine powered by older people, chronic diseases, supply discipline, patient demand and other factors.“End TopiliusThe
[publish_date
